Trial Profile
A 2-year, Multi-center, Phase II, Open-label, Fixed-dose, Randomized Comparative Trial of Azacitidine, With or Without Deferasirox in Patients With Higher Risk Myelodysplastic Syndromes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary) ; Deferasirox (Primary) ; Azacitidine; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Dec 2016 Status changed to discontinued since only one patient has been enrolled in trial, stopped for Safety and no analysis will ever be done.
- 01 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2015 Planned number of patients changed from 190 to 60 as reported by ClinicalTrials.gov record.